Skip to main
AKTX

Akari Therapeutics (AKTX) Stock Forecast & Price Target

Akari Therapeutics (AKTX) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Akari Therapeutics PLC is advancing its lead product candidate, AKTX-101, a promising Trop2-targeting antibody-drug conjugate (ADC), which has shown strong preclinical efficacy against various solid tumors, including bladder and gastric cancers. The ability of AKTX-101 to generate immunological memory and improve tumor recognition when combined with immuno-oncology agents positions it favorably within the oncology landscape. This innovative approach, leveraging novel cancer-killing toxins, could lead to best-in-class therapeutic outcomes and enhance the overall efficacy of ADCs beyond current treatment options.

Bears say

Akari Therapeutics PLC's stock faces a negative outlook primarily due to its weak balance sheet, which raises significant financial risks. The company's need for additional funds to support ongoing and planned preclinical and clinical programs creates a potential financial overhang that could adversely affect its stock price. Although there is promise in Akari's antibody-drug conjugate platform, the reliance on securing further financing underscores the vulnerability of the company's financial situation.

Akari Therapeutics (AKTX) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Akari Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Akari Therapeutics (AKTX) Forecast

Analysts have given Akari Therapeutics (AKTX) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Akari Therapeutics (AKTX) has a Strong Buy consensus rating as of Jan 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.30, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.30, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Akari Therapeutics (AKTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.